Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: SEC Rules

SEC Rules

posted on Dec 19, 2007 09:18AM

As far as SEC goes, wouldn't filing an 8-K showing attaching the PR's release satisfy disclosure issues.  Following up with financial details in the 10Q in Jan & April as applicable should satisfy the rest.

 

In reality, that's what's happened with ALL other signings as well.  It's simply the confidentiality agreement is REALLY being stressed this time around.  In a way, that's emphasizing the scale of this deal over others.

 

Corrections

Share
New Message
Please login to post a reply